{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:07Z","timestamp":1786994407066,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"am","delay-in-days":311,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102482","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T02:44:44Z","timestamp":1599101084000},"page":"102482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Beyond COVID-19: DO MS\/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-0328","authenticated-orcid":false,"given":"Elisabeth","family":"Maillart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Papeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lubetzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Pourcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Louapre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102482_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102073","article-title":"The COVID-19 pandemic and the use of MS disease-modifying therapies","volume":"39","author":"Giovannoni","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"10.1016\/j.msard.2020.102482_bib0002","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.msard.2020.102482_bib0003","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.msard.2020.102482_bib0004","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/ar4427","article-title":"Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis","volume":"16","author":"Kapetanovic","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.msard.2020.102482_bib0005","doi-asserted-by":"crossref","unstructured":"Kirkcaldy, R.D., King, B.A., Brooks, J.T., 2020. COVID-19 and Postinfection Immunity: limited Evidence, Many Remaining Questions. JAMA.","DOI":"10.1001\/jama.2020.7869"},{"key":"10.1016\/j.msard.2020.102482_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","author":"Long","year":"2020","journal-title":"Nat Med."},{"key":"10.1016\/j.msard.2020.102482_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102323","article-title":"Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report","volume":"44","author":"Lucchini","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2020.102482_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102341","article-title":"Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab","volume":"44","author":"Thornton","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2020.102482_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current State of the Science","author":"Vabret","year":"2020","journal-title":"Immunity."},{"issue":"1","key":"10.1016\/j.msard.2020.102482_bib0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/cei.12390","article-title":"Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients","volume":"178","author":"Westra","year":"2014","journal-title":"Clin Exp Immunol"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:52:05Z","timestamp":1761900725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820305575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":10,"alternative-id":["S2211034820305575"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102482","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond COVID-19: DO MS\/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102482","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102482"}}